期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 143, 期 -, 页码 134-160出版社
ELSEVIER
DOI: 10.1016/j.addr.2019.05.012
关键词
Nanomedicine; Drug delivery; Liposome; PET; SPECT; Nuclear imaging; Theranostics
资金
- CRUK Multidisciplinary Project Award [C48390/A21153]
- King's College London & Imperial College London EPSRC Centre for Doctoral Training in Medical Imaging [EP/L015226/1]
- EPSRC [EP/R045046/1, EP/S032789/1]
- KCL/UCL Comprehensive Cancer Imaging Centre - CRUK
- MRC (England)
- DoH (England)
- GlaxoSmithKline plc
- Wellcome/EPSRC Centre for Medical Engineering at KCL [WT 203148/Z/16/Z]
- Medical Research Council Confidence in Concepts scheme
- Experimental Cancer Medicine Centre at KCL
- KHP/KCL CRUK Cancer Centre
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and KCL [IS-BRC-1215-20006]
- EPSRC [EP/S032789/1, EP/R045046/1] Funding Source: UKRI
- MRC [MC_PC_14105] Funding Source: UKRI
The integration of nuclear imaging with nanomedicine is a powerful tool for efficient development and clinical translation of liposomal drug delivery systems. Furthermore, it may allow highly efficient imaging-guided personalised treatments. In this article, we critically review methods available for radiolabelling liposomes. We discuss the influence that the radiolabelling methods can have on their biodistribution and highlight the often-overlooked possibility of misinterpretation of results due to decomposition in vivo. We stress the need for knowing the biodistribution/pharmacokinetics of both the radiolabelled liposomal components and free radionuclides in order to confidently evaluate the images, as they often share excretion pathways with intact liposomes (e.g. phospholipids, metallic radionuclides) and even show significant tumour uptake by themselves (e.g. some radionuclides). Finally, we describe preclinical and clinical studies using radiolabelled liposomes and discuss their impact in supporting liposomal drug development and clinical translation in several diseases, including personalised nanomedicine approaches. (C) 2019 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据